Loading
Ascendo Biotechnology makes an antibody that releases a brake on the body's first-line immune cells, aiming to help the immune system attack solid tumours that resist current immunotherapy.
Ascendo Biotechnology Inc., headquartered in Taipei, was founded in 2019 as a spin-out from BRIM Biotechnology, according to the company, by Dr Yen-Ta Lu of MacKay Memorial Hospital. It targets the TLT-1/CD11b innate immune checkpoint axis. ASD141, a first-in-class anti-CD11b monoclonal antibody that blocks TLT-1 signalling, is in a first-in-human phase 1 trial in advanced solid tumours (NCT06235437); ASD001, a CD11b-activating antibody for autoimmune disease, is preclinical. In May 2026 it completed an oversubscribed Series A with investors including Taiwania Capital (TaiAx Life Science Fund), Yuanta Venture Capital and Industrial Technology Investment Corporation. Its first registered cancer trial, NCT06235437, was posted on ClinicalTrials.gov in February 2024.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · Oversubscribed; amount not stated in the release | 2026 | undisclosed | ascendobiotech.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/